A new generation of recombinant polypeptides combines multiple protein domains for effective antimicrobial activity by Roca-Pinilla, Ramon et al.
Roca‑Pinilla et al. Microb Cell Fact          (2020) 19:122  
https://doi.org/10.1186/s12934‑020‑01380‑7
RESEARCH
A new generation of recombinant 
polypeptides combines multiple protein 
domains for effective antimicrobial activity
Ramon Roca‑Pinilla, Adrià López‑Cano, Cristina Saubi, Elena Garcia‑Fruitós*  and Anna Arís*
Abstract 
Background: Although most of antimicrobial peptides (AMPs), being relatively short, are produced by chemical 
synthesis, several AMPs have been produced using recombinant technology. However, AMPs could be cytotoxic to 
the producer cell, and if small they can be easily degraded. The objective of this study was to produce a multidomain 
antimicrobial protein based on recombinant protein nanoclusters to increase the yield, stability and effectivity.
Results: A single antimicrobial polypeptide JAMF1 that combines three functional domains based on human 
α‑defensin‑5, human XII‑A secreted phospholipase A2  (sPLA2), and a gelsolin‑based bacterial‑binding domain along 
with two aggregation‑seeding domains based on leucine zippers was successfully produced with no toxic effects for 
the producer cell and mainly in a nanocluster structure. Both, the nanocluster and solubilized format of the protein 
showed a clear antimicrobial effect against a broad spectrum of Gram‑negative and Gram‑positive bacteria, including 
multi‑resistant strains, with an optimal concentration between 1 and 10 µM.
Conclusions: Our findings demonstrated that multidomain antimicrobial proteins forming nanoclusters can be 
efficiently produced in recombinant bacteria, being a novel and valuable strategy to create a versatile, highly stable 
and easily editable multidomain constructs with a broad‑spectrum antimicrobial activity in both soluble and nano‑
structured format.
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Background
The growing number of antibiotic-resistant pathogens is a 
pressing healthcare challenge. As a consequence, the devel-
opment of novel antimicrobial drugs is more necessary 
than ever, especially against multidrug-resistant (MDR) 
microorganisms. One source of potential broad-spectrum 
antibacterials with increasing promise are antimicro-
bial peptides (AMPs), which are peptides from the innate 
immune system of nearly all multicellular organisms [1, 
2]. AMPs also known as host defense peptides (HDPs), are 
cationic amphiphilic peptides [3]. These positively charged 
peptides are classified into defensins (alpha-defensins and 
beta-defensins), cathelicidins, and histatins [1]. Because 
they interact and disrupt the negatively charged bacte-
rial cell envelope, they have broad-spectrum antibacterial 
activity [4, 5]. Although AMPs hold therapeutic potential, 
even against MDR bacteria [4–6], important drawbacks 
largely hinder final in  vivo applications [3]. Most of the 
currently used AMP are produced by chemical synthesis, 
being molecules highly susceptibility to proteolytic deg-
radation by microbial and host enzymes (short half-life) 
[7]. Besides, due to the high doses needed they are fre-
quently toxic and high production costs are still a problem 
for large-scale development [8]. Alternatively, AMPs can 
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be recombinantly produced [9–11]. Still, their small size 
makes them easily degradable, and their recombinant pro-
duction is limited because they are toxic for the producer 
bacterial cell due to their antimicrobial nature. To address 
these shortcomings, different approaches to make the pro-
duction of recombinant AMPs linked to a carrier that sta-
bilizes the peptide have been described. Some examples of 
carriers for these fusion proteins are small ubiquitin-like 
modifier (SUMO), thioredoxin (Trx), glutathione S-trans-
ferase (GST), biotin carboxyl carrier protein (BCCP), green 
fluorescent protein (GFP), calmodulin and human serum 
albumin [12–15]. Another strategy to efficiently produce 
these peptides is the use of acidic partners [16]. In all the 
cases, these carriers or partners help to overcome the tox-
icity of the AMP and at the same time increase their pro-
tein expression yields [16–18]. However, to retrieve the 
AMP of interest, it is often necessary to remove these car-
riers, which requires expensive enzymatic cleavage or toxic 
reagents [19].
To address this gap, here, we have explored a new strat-
egy for the production of a recombinant antimicrobial pro-
tein based on a multidomain polypeptide that combines 
different functional domains in a single molecule but with-
out a carrier protein. The combination of several domains 
has been previously reported for other proteins [20–23], 
but none of them for antimicrobial treatment purposes. 
Additionally, taking into consideration the specific require-
ments of price, stability, toxicity, effectiveness, and deliv-
ery that appear to be key parameters in the development 
of a new generation of antimicrobials [3], we have added 
aggregation-seeding domains based on leucine zippers that 
increase the recombinant production of the antimicrobial 
molecules as protein nanoclusters (also known as inclu-
sion bodies (IBs)) [24]. IBs are non-enveloped, porous and 
mechanically stable protein nanoparticles, mainly formed 
by the polypeptide of interest and generated during recom-
binant protein production process, having the potential 
to be a protein-slow release form when administered [25]. 
Another advantage of this protein format is its produc-
tion through a one step-process. This means that, in con-
trast to most of encapsulation strategies, which involve two 
separate processes (the production of the carriers and the 
biomolecule separately), IB production is achieved in one 
single step. Finally, it has also been previously proven that 
IBs can be used as a source of soluble protein after a mild 
extraction protocol in non-denaturing conditions [26, 27].
Results and discussion
Construct design and protein production of JAMF1 
as protein nanocluster
Our construct, named JAMF1 and formed by the com-
bination of an  HDP (HD5) [28], a bacterial binding 
domain (gelsolin) [29] and an enzymatic antimicrobial 
peptide  (sPLA2) [30], flanked by two aggregation-seed-
ing domains (c-Jun and c-Fos leucine zippers at N- and 
C-terminal, respectively), has been designed (Fig.  1 and 
Additional file 1: Figure S1). During their production in 
a recombinant bacterial system, no toxicity effects were 
observed in the producer cell (data not shown) and, as 
desired, the multidomain JAMF1 protein (54  kDa) was 
mainly produced as protein IBs (Additional file  1: Fig-
ure S2). The percentage of JAMF1 aggregation as IBs was 
74 ± 3.1% of the total multidomain protein overproduced, 
reaching a yield of 96.5  mg/l and a purity of 95% once 
purified. FESEM micrographs of the purified JAMF1 IBs 
showed a porous morphology with a round shape and a 
particle size of around 500 nm (Fig. 1).
Antibacterial activity of JAMF1 nanoclusters
To determine the antimicrobial activity of JAMF1 IBs, we 
evaluated the survival of both Gram-positive and Gram-
negative pathogenic bacteria treated with JAMF1 IBs, 
following the procedure described in Fig.  2a. First, the 
survival of an E. coli DH5α model strain in presence of 
increasing concentrations of JAMF1 IBs was determined 
and a dose dependent effect was observed (p ≤ 0.01) 
(Fig.  2b). Using the concentration of JAMF1 IBs giving 
the lowest values of E. coli survival (10  μM), we tested 
the antibacterial effect of these nanoparticles with dif-
ferent Gram-positive strains, including extended-spec-
trum beta-lactam-resistant Enterococcus spp. (SHV-12), 
extended-spectrum beta-lactam-resistant Enterococcus 
spp. (CTX-M-14), and E. faecalis (ECF), and Gram-neg-
ative strains, including Carbapenem-resistant Klebsiella 
pneumoniae (KPC), quinolone-resistant K. pneumoniae 
(qnrA), and extended-spectrum beta-lactam-resistant E. 
coli (CMY2) (Fig. 2c). In all strains tested we observed a 
clear decrease in the survival (p ≤ 0.001), reaching viabil-
ity reduction values of 96.3 ± 0.2% for KPC, 91 ± 0.2% 
for qnrA, 85.3 ± 0.6 for CMY2, 82.8 ± 2% for SHV-12, 
89.8 ± 0.9% for ECF, and 94.4 ± 0.7% for CTX-M-14 
(Fig. 2c).
Anti‑biofilm activity of JAMF1 nanoclusters
To further evaluate the potential of this new class of 
antimicrobial proteins we have assessed the capacity of 
JAMF1 nanoclusters to inhibit biofilm formation. For 
that, KPC was grown in multiwell plates in which JAMF1 
IBs were previously immobilized, as detailed in Fig.  3a. 
The results obtained showed a decrease of 81.4 ± 2.3% in 
biofilm formation (p ≤ 0.0001) when surfaces were deco-
rated with JAMF1 IBs (Fig. 3b), which confirms that anti-
microbial nanoclusters are also active when deposited on 
plastic surfaces to inhibit biofilm formation.
Several works have studied the IBs appealing features 
in contexts such as cancer [31], tissue regeneration [32], 
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Fig. 1 Construct design. Schematic representation of JAMF1 protein construct and protein production format. Inset image: FESEM micrography of 
purified JAMF1 nanoparticles
Fig. 2 Antibacterial activity of JAMF1 nanoclusters. a Graphic representation of the BacTiter‑Glo™ Microbial Cell viability assay. b Bacterial survival 
(%) of E. coli DH5α in the presence of JAMF1 IBs at a range of 0‑10 µM. Different letters describe significant differences (p ≤ 0.01). c Bacterial survival 
of KPC, qnrA, CMY2, SHV‑12, ECF and CTX‑M‑14 bacterial strains in the presence of 10 µM of JAMF1 IBs. Survival of JAMF1 treated bacterial cells 
(black bars) is significantly different from the negative control (grey bars) (p ≤ 0.001)
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and immunostimulation [33], demonstrating its great 
potential as a new biomaterial. However, to the best of 
our knowledge, this is the first study exploring the anti-
microbial effect of a multidomain protein embedded in 
IBs. Whereas previous studies have used fusion partners 
such as SUMO [12], Trx, GST [13], and human serum 
albumin [14] to overcome the difficulties to express rel-
atively short peptides, the current work shows that it is 
also possible to produce a non-toxic and stable AMP-
based molecule as a combination of several AMPs. This 
offers versatility in the construction of molecules and 
the possibility to explore several combinations to merge 
complementary antimicrobial activities without the 
need to use biologically irrelevant carrier proteins. The 
production of this new generation of antimicrobial multi-
domain polypeptides as nanoclusters seems to be a good 
strategy to escape proteolytic and host-toxicity pathways 
in the recombinant bacterial host.
Solubilized JAMF1 antibacterial activities
For some specific applications a soluble version of the 
multidomain antimicrobial polypeptide would be more 
appropriate than the nanostructured or IBs version, 
for example those applications in which an intrave-
nous administration of the protein would be necessary. 
Interestingly, the IB format has also been previously 
described as a reservoir of functional protein [25] and, 
in consequence, an appealing source of the soluble ver-
sion of proteins tricky to produce, available after using a 
mild-extraction protocol [26]. Considering that JAMF1 
is mainly produced as IBs (74% of the total protein over-
produced), we also explored if JAMF1 IBs could be used 
as a source to obtain pure antimicrobial multidomain 
polypeptide in its soluble form using a non-denaturing 
protocol and evaluate its antimicrobial potential (Fig. 4a). 
The results proved that the purified soluble version could 
not only be isolated from IBs (Additional file 1: Figure S2) 
but also showed antimicrobial activity against either E. 
coli (p ≤ 0.0001) and KPC (p ≤ 0.001) in a dose-depend-
ent manner, where the growth inhibition reached values 
of 78.7 ± 2% and 91.3 ± 8.5% for E. coli and KPC at 3 and 
2 μM, respectively (p < 0.0001) (Fig. 4b). Interestingly, the 
antimicrobial efficiency of this new multidomain antimi-
crobial molecule is pretty similar at 3 μM, achieving effi-
ciencies of around 78% in both cases (Figs.  2b and 4b). 
This contrasts with the majority of examples comparing 
the activity of soluble and IB formats, in which the 
soluble version is usually more biologically active that its 
nanoclustered counterpart [34].
Conclusions
Our findings demonstrated that multidomain antimicro-
bial proteins produced as nanoclusters can be efficiently 
obtained in recombinant bacteria, being a valuable strat-
egy to create a versatile, highly stable and easily editable 
constructs with antimicrobial activity against both Gram-
positive and Gram-negative bacteria. Moreover, we have 
proven that the antimicrobial protein forming the IBs can 
be easily solubilized to obtain also active proteins in its 
soluble form.
Methods
Bacterial strains and medium
Escherichia coli BL21 (DE3) was used for heterologous 
protein expression. Strains used for antibacterial and 
antibiofilm activity assays were E. coli DH5α, Carbape-
nem-resistant Klebsiella pneumoniae (KPC), quinolone-
resistant K. pneumoniae (qnrA), extended-spectrum 
Fig. 3 Anti‑biofilm activity of JAMF1 nanoclusters. a Biofilm inhibition assay. Plate wells were incubated for 2 h with JAMF1 IBs and then a diluted 
(1:200) KPC cell culture with 0.2% glucose was added and incubated for 24 h to allow biofilm formation. b Biofilm formation ability (%) of KPC after 
treating plastic wells with JAMF1 IBs (black bar) vs non‑treated wells (grey bar). ****Indicates significant differences (p ≤ 0.0001)
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beta-lactam-resistant E. coli (CMY2), extended-spec-
trum beta-lactam-resistant Enterococcus spp. (SHV-12), 
extended-spectrum beta-lactam-resistant Enterococcus 
spp. (CTX-M-14) and E. faecalis (ECF). All strains were 
grown in Brain–Heart Infusion (BHI) broth (Scharlau, 
Barcelona, Spain), except for E. coli strains, which were 
grown in Luria–Bertani (LB) medium.
Genetic construct design
From N-terminal to C-terminal, the gene for the 
JAMF1 (Additional files 2, 3, 4)  construct consisted 
of the sequences encoding Jun257-318 (Uniprot entry 
P05412), human α-defensin-5 (HD5) precursor (Uniprot 
entry Q01523), gelsolin188-196 (Uniprot entry P06396), 
human XII-A secreted phospholipase  A2  (sPLA2) pre-
cursor (Uniprot entry Q9BZM1) and Fos118-210 (Uni-
prot entry P01100). A linker sequence (SGGGSGGS) 
was used between each of the domains and a C-terminal 
H6-Tag for protein purification. The fusion construct was 
codon optimized by GeneArt (Lifetechnologies, Regens-
burg, Germany) and cloned into pET22b  (AmpR) (Nova-
gene, Darmstadt, Germany) vector.
Inclusion body production and purification
Escherichia coli BL21 (DE3)/pET22b-JAMF1 (Additional 
file 3) culture (0.5 l) was grown at 37 °C and 250 rpm in 
LB broth with ampicillin at 100  μg/mL. Protein expres-
sion was induced by 1 mM isopropyl-β-d-thiogalactoside 
(IPTG) at an  OD600 = 0.4–0.6. Cultures were grown 3  h 
post-induction and after that processed as previously 
described [35]. Briefly, protease inhibitors (Complete 
EDTA-free, Roche), and phenylmethanesulphonyl-flu-
oride (PMSF) and lysozyme were added to the culture 
at a final concentration of 0.4  mM (Sigma-Aldrich) and 
1 µg/ml (Sigma-Aldrich), respectively. After 2 h of incu-
bation at 37 °C and 250 rpm the culture was centrifuged 
and resuspended in 50  ml of PBS supplemented with 
protease inhibitors. Then, the mixture was ice-jacketed 
and sonicated for 4 cycles of 1.5  min at 10% amplitude 
under 0.5 s cycles. After sonication, the mixture was fro-
zen overnight (ON) at − 80 °C. The mixture was thawed 
and Triton X-100 was added (0.4% (v/v)) and incubated 
for 1 h at room temperature (RT). After this treatment, 
the mixture was frozen at − 80  °C for 2  h and then 
thawed between for several cycles until no viable bacte-
rial growth was detected. After that, 125  µl of Nonidet 
P40 (NP-40) was added and incubated for 1  h at 4  °C. 
Then, DNA was removed with DNAse at a final concen-
tration of 0.6 µg/ml and  MgSO4 0.6 mM for 1 h at 37 °C 
and 250 rpm. Samples were centrifuged at 15,000×g for 
15 min at 4 °C. The pellet containing IBs was washed with 
25 ml lysis buffer (50 mM Tris–HCl pH 8, 100 mM NaCl, 
1 mM EDTA and Triton X-100 0.5% (v/v)). Finally, a cen-
trifugation at 15,000×g and 4 °C for 15 min was carried 
out obtaining pellets that were stored at − 80  °C until 
analysis. Purified IBs were quantified by western blot 
using a monoclonal anti-His antibody (His-probe, Santa 
Cruz).
IB solubilization and purification of the solubilized JAMF1
Escherichia coli BL21 (DE3)/pET22b-JAMF1 culture 
(2  l) was grown as previously described. The whole vol-
ume was centrifuged at 6000×g and the pellet was 
resuspended in 120  ml of PBS 1x in presence of pro-
tease inhibitors. Samples of 30  ml were subjected to 4 
rounds of sonication for 5  min at 10% amplitude under 
0.5  s cycle, intercalated by a minimum of 5  min repose 
in ice. Protein pellets were recovered and washed twice 
with distilled water. Pellets were weighted and solubilized 
in 0.2% N-lauroyl sarcosine, 40  mM Tris and protease 
inhibitors at a ratio of 40 ml/g of wet pellet as previously 
described [27]. The mixture was incubated 40  h ON at 
RT under agitation and the supernatant was recovered 
through centrifugation at 15,000×g for 45  min at 4  °C 
Fig. 4 Solubilized JAMF1 antibacterial activities. a Schematic representation of JAMF1 IB solubilization at RT. b Bacterial survival (%) of E. coli 
DH5α and KPC at different concentrations (0, 0.5, 1, 2 and 3 µM) of solubilized JAMF1. Capital letters depict significant differences for E. coli DH5α 
(p ≤ 0.0001) and lower case for KPC (p ≤ 0.001). Filled circles correspond to E. coli DH5α and empty circles correspond to KPC
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for further purification. NaCl and imidazole were added 
to the solubilized protein to equilibrate the samples with 
the binding buffer composition, and Immobilized Metal 
Affinity Chromatography (IMAC) purification was car-
ried in an ÄKTA purifier FPLC (GE Healthcare, Chicago, 
IL, USA) using 1  ml HisTrap HP columns (GE Health-
care). Both the binding and the elution buffer contained 
0.2% N-lauroyl sarcosine, and the final imidazole con-
centration in the elution buffer was 0.5 M. The buffer of 
the selected fractions was changed to 10 mM KPi (K/PO4 
buffer pH 7.4) using a desalting column (GE Healthcare). 
The amount of purified protein was determined by Brad-
ford’s assay, and the integrity of the protein analyzed by 
SDS-PAGE [26].
Antibacterial activity assay
The bacterial cell viability was assessed with the BacTi-
ter-Glo™ Microbial Cell Viability assay (Promega, Man-
nheim, Germany), according to the manufacturer’s 
protocol. Shortly, bacterial cells were grown O/N at 37 °C 
and 250 rpm and then diluted 1:100 in KPi buffer. Then, 
150 µl from the KPi diluted cells were centrifuged in 
1  ml tubes at 6200×g at 4  °C for 15  min. Subsequently, 
the supernatant was removed, and the pelleted cells 
were then resuspended with 150  µl of either KPi buffer 
(negative control) or 150 µl of JAMF1 IBs at 1, 3, 5 and 
10 µM. After 5 h incubation at 37  °C in a 96-well plate, 
100 µl were taken and mixed with 100 µl of the BacTiter-
GloTM reagent. Finally, luminescence was measured in a 
microplate luminometer  (LUMIstar®, BMG LABTECH. 
Ortenberg, Germany). The measured arbitrary lumines-
cence values were normalized against the control (KPi 
treatment).
Biofilm formation assay
KPC was used as a model strain. Briefly, an O/N was 
grown at 37  °C and 250  rpm. Before adding bacteria to 
a 24-well sterile plate for biofilm formation, IB-treated 
wells were incubated 2 h at RT with 80 µl/well of 500 µM 
of JAMF1 IBs. After that, bacteria from the O/N cul-
ture were diluted 1:200 in BHI supplemented with 0.2% 
(w/v) glucose and grown in 24-well sterile plate (400  µl 
final volume) and incubated at 37  °C for 24 h. After the 
incubation, the supernatant was removed and wells were 
washed three times with 500 µl NaCl 0.9%, then fixated 
with 500  µl methanol for 10  min at RT. Methanol was 
removed and the plate was dried at 37  °C for 15  min. 
Finally, the remaining cells in the well were stained with 
1% (v/v) crystal violet for 15  min at RT, washed three 
times with sterile MQ-H2O. Finally, stained cells were 
diluted in 33% (v/v) acetic acid and the absorbance was 
measured at 595 nm [36]. All measurements were done 
by triplicate and in sterile conditions.
Electron microscopy
Microdrops of JAMF1 IB suspensions were air-dried on 
silicon wafers and micrographed in a FESEM Zeiss Mer-
lin (Zeiss) running at 1 kV
Statistical analysis
For all assays, each condition was performed in tripli-
cate and represented as the mean ± standard error of the 
mean. All data were checked for normality. All p-values 
correspond to ANOVA analyses, except for the biofilm 
formation assay where a t-test was performed. Letters 
correspond to Tukey test analyses.
Supplementary information
Supplementary information accompanies this paper at https ://doi.
org/10.1186/s1293 4‑020‑01380 ‑7.
Additional file 1: Figure S1. Aminoacidic sequence of JAMF1 for each of 
the construct domains. Figure S2. Western Blots of JAMF1. (a) Expression 
time course of JAMF1 at 0, 1, 3 and 5 h post‑induction with IPTG in the 
insoluble and soluble fractions. MWM = Molecular Weight Marker (kDa), 
IF = Insoluble fraction, SF = Soluble fraction. (b) Western blot of the puri‑
fied JAMF1 by IMAC (PP) and the purified IBs (PIBs). 
Additional file 2. DNA coding sequence of JAMF1. 
Additional file 3. DNA coding sequence of pET22b‑JAMF1. 
Additional file 4. JAMF1 aminoacid sequence.
Abbreviations
AMP: Antimicrobial peptide; sPLA2: Human XII‑A secreted phospholipase A2; 
MDR: Multidrug resistant; IB: Inclusion body; KPC: Carbapenem‑resistant Kleb-
siella pneumoniae; qnrA: Quinolone‑resistant K. pneumoniae; CMY2: Extended‑
spectrum beta‑lactam‑resistant Escherichia coli; SHV‑12: Extended‑spectrum 
beta‑lactam‑resistant Enterococcus spp; CTX‑M‑1: Extended‑spectrum beta‑
lactam‑resistant Enterococcus spp; ECF: Enterococcus faecalis; BHI: Brain–Heart 
Infusion; LB: Luria–Bertani broth; HD5: Human α‑defensin‑5; IPTG: Isopropyl‑β‑
d‑thiogalactoside; SUMO: Small ubiquitin‑like modifier; Trx: thioredoxin; GST: 
Glutathione S‑transferase; BCCP: Biotin carboxyl carrier protein; GFP: Green 
fluorescent protein.
Acknowledgements
The authors are indebted to ICTS ‘‘NANBIOSIS”, more specifically the Protein 
Production Platform of CIBER in Bioengineering, Biomaterials & Nanomedicine 
(CIBER‑ BBN)/IBB, at the UAB sePBioEs scientific‑technical service (http://www.
nanbi osis.es/unit/u1‑prote in‑produ ction ‑platf orm‑ppp/) and to ‘‘Servei de 
Microscopia” (UAB).
Authors’ contributions
RRP carried out most of the experiments, performed the data analysis and 
prepared a draft of the manuscript. ALC and CS performed experiments 
of antimicrobial activity and protein production, respectively. EGF and AA 
directed the study and prepared the final manuscript. All authors read and 
approved the final manuscript.
Funding
This work was supported by an IRTA Cutting Edge Research project. We are 
indebted to CERCA Programme (Generalitat de Catalunya) and the European 
Social Fund for supporting our research. RRP and ALC received a PhD fellow‑
ship from Secretaria d’Universitats i Recerca del Departament d’Economia i 
Coneixement de la Generalitat de Catalunya (AGAUR) and EGF a post‑doctoral 
fellowship from INIA (DOC‑INIA).
Page 7 of 7Roca‑Pinilla et al. Microb Cell Fact          (2020) 19:122  
Availability of data and materials
The datasets used and/or analysed during the current study are available from 
the corresponding author on reasonable request.
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Received: 19 April 2020   Accepted: 27 May 2020
References
 1. De Smet K, Contreras R. Human antimicrobial peptides: defensins, cathelici‑
dins and histatins. Biotechnol Lett. 2005;27(18):1337–47.
 2. Haney EF, Mansour SC, Hancock REW. Antimicrobial peptides: an introduc‑
tion. In: Methods in molecular biology. 2017. p. 3–22. http://www.ncbi.nlm.
nih.gov/pubme d/28013 493.
 3. Kumar P, Kizhakkedathu J, Straus S. Antimicrobial peptides: diversity, mecha‑
nism of action and strategies to improve the activity and biocompatibility 
in vivo. Biomolecules. 2018;8(1):4.
 4. Jiang Z, Mant CT, Vasil M, Hodges RS. Role of positively charged residues 
on the polar and non‑polar faces of amphipathic α‑helical antimicrobial 
peptides on specificity and selectivity for Gram‑negative pathogens. Chem 
Biol Drug Des. 2018;91:75–92.
 5. Greber KE, Dawgul M, Kamysz W, Sawicki W. Cationic net charge and 
counter ion type as antimicrobial activity determinant factors of short 
lipopeptides. Front Microbiol. 2017;8:123
 6. Lázár V, Martins A, Spohn R, Daruka L, Grézal G, Fekete G, et al. Antibiotic‑
resistant bacteria show widespread collateral sensitivity to antimicrobial 
peptides. Nat Microbiol. 2018;3(6):718–31.
 7. da Costa JP, Cova M, Ferreira R, Vitorino R. Antimicrobial peptides: 
an alternative for innovative medicines? Appl Microbiol Biotechnol. 
2015;99(5):2023–40.
 8. Vlieghe P, Lisowski V, Martinez J, Khrestchatisky M. Synthetic therapeutic 
peptides: science and market. Drug Discov Today. 2010;15(1–2):40–56.
 9. Cao J, de la Fuente‑Nunez C, Ou RW, Torres MDT, Pande SG, Sinskey AJ, et al. 
Yeast‑based synthetic biology platform for antimicrobial peptide produc‑
tion. ACS Synth Biol. 2018;7(3):896–902. https ://doi.org/10.1021/acssy 
nbio.7b003 96.
 10. Balandin SV, Finkina EI, Nurmukhamedova EKA, Tagaev AA, Umnyakova ES, 
Kokryakov VN, et al. Biotechnological method of preparation and charac‑
terization of recombinant antimicrobial peptide avicin A from Enterococcus 
avium. Dokl Biochem Biophys. 2019;484(1):42–4.
 11. Anju A, Smitha CK, Preetha K, Boobal R, Rosamma P. Molecular characteriza‑
tion, recombinant expression and bioactivity profile of an antimicrobial 
peptide, Ss‑arasin from the Indian mud crab, Scylla serrata. Fish Shellfish 
Immunol. 2019;88:352–8.
 12. Satakarni M, Curtis R. Production of recombinant peptides as fusions with 
SUMO. Protein Expr Purif. 2011;78(2):113–9. https ://doi.org/10.1016/j.
pep.2011.04.015.
 13. Li Y. Production of human antimicrobial peptide LL‑37 in Escherichia coli 
using a thioredoxin—SUMO dual fusion system. PROTEIN Expr Purif. 
2013;87(2):72–8. https ://doi.org/10.1016/j.pep.2012.10.008.
 14. Wang M, Zheng K, Lin J, Huang M, Ma Y, Li S, et al. Rapid and efficient pro‑
duction of cecropin A antibacterial peptide in Escherichia coli by fusion with 
a self‑aggregating protein. BMC Biotechnol. 2018;18(1):62.
 15. Sinha R, Shukla P. Antimicrobial peptides: recent insights on biotech‑
nological interventions and future perspectives. Protein Pept Lett. 
2019;26(2):79–87.
 16. Wang Y‑Q, Cai J‑Y. High‑level expression of acidic partner‑mediated 
antimicrobial peptide from tandem genes in Escherichia coli. Appl Biochem 
Biotechnol. 2007;141(2–3):203–13.
 17. Arias M, Hoffarth ER, Ishida H, Aramini JM, Vogel HJ. Recombinant expres‑
sion, antimicrobial activity and mechanism of action of tritrpticin analogs 
containing fluoro‑tryptophan residues. Biochim Biophys Acta Biomembr. 
2016;1858:1012–23.
 18. Yi T, Sun S, Huang Y, Chen Y. Prokaryotic expression and mechanism of 
action of aα‑helical antimicrobial peptide A20L using fusion tags. BMC 
Biotechnol. 2015;15(1):1–10. https ://doi.org/10.1186/s1289 6‑015‑0189‑x.
 19. Li Y. Self‑cleaving fusion tags for recombinant protein production. Biotech‑
nol Lett. 2011;33(5):869–81.
 20. Lee H‑B, Piao D‑C, Lee J‑Y, Choi J‑Y, Bok J‑D, Cho C‑S, et al. Artificially 
designed recombinant protein composed of multiple epitopes of foot‑and‑
mouth disease virus as a vaccine candidate. Microb Cell Fact. 2017;16(1):33.
 21. Kempe T, Kent SBH, Chow F, Peterson SM, Sundquist WI, L’Italien JJ, et al. 
Multiple‑copy genes: production and modification of monomeric peptides 
from large multimeric fusion proteins. Gene. 1985;39(2–3):239–45.
 22. Skowron PM, Krawczun N, Zebrowska J, Krefft D, Zołnierkiewicz O, Bielawa 
M, et al. A vector‑enzymatic DNA fragment amplification‑expression tech‑
nology for construction of artificial, concatemeric DNA, RNA and proteins 
for novel biomaterials, biomedical and industrial applications. Mater Sci Eng 
C. 2020;108:110426.
 23. Domingo‑Espín J, Vazquez E, Ganz J, Conchillo O, García‑Fruitós E, Cedano J, 
et al. Nanoparticulate architecture of protein‑based artificial viruses is sup‑
ported by protein–DNA interactions. Nanomedicine. 2011;6(6):1047–61.
 24. Choi S, Lee SJ, Yeom S, Kim HJ, Rhee YH, Jung H, et al. Controlled localization 
of functionally active proteins to inclusion bodies using leucine zippers. 
PLoS ONE. 2014;9(6):e97093.
 25. Rinas U, Garcia‑Fruitós E, Corchero JL, Vázquez E, Seras‑Franzoso J, Villaverde 
A. Bacterial inclusion bodies: discovering their better half. Trends Biochem 
Sci. 2017;42(9):726–37.
 26. Gifre‑Renom L, Cano‑Garrido O, Fàbregas F, Roca‑Pinilla R, Seras‑Franzoso J, 
Ferrer‑Miralles N, et al. A new approach to obtain pure and active proteins 
from Lactococcus lactis protein aggregates. Sci Rep. 2018;8(1):13917.
 27. Peternel Š, Grdadolnik J, Gaberc‑Porekar V, Komel R. Engineering inclusion 
bodies for non denaturing extraction of functional proteins. Microb Cell 
Fact. 2008;7:1–9.
 28. Selsted ME, Ouellette AJ. Mammalian defensins in the antimicrobial 
immune response. Nat Immunol. 2005;6:551. https ://doi.org/10.1038/ni120 
6.
 29. Bucki R, Byfield FJ, Kulakowska A, Mccormick ME, Drozdowski W, Hartung 
T, et al. Extracellular gelsolin binds lipoteichoic acid and modulates cellular 
response to proinflammatory bacterial wall components. J Immunol. 
2008;181(7):4936–44.
 30. Huhtinen HT, Grönroos JO, Grönroos JM, Uksila J, Gelb MH, Nevalainen TJ, 
et al. Antibacterial effects of human group IIA and group XIIA phospholi‑
pase A2 against Helicobacter pylori in vitro. APMIS. 2006;114(2):127–30.
 31. Pesarrodona M, Jauset T, Díaz‑Riascos ZV, Sánchez‑Chardi A, Beaul‑
ieu M, Seras‑Franzoso J, et al. Targeting antitumoral proteins to breast 
cancer by local administration of functional inclusion bodies. Adv Sci. 
2019;6(18):1900849.
 32. Seras‑Franzoso J, Peebo K, García‑Fruitós E, Vázquez E, Rinas U, Villaverde 
A. Improving protein delivery of fibroblast growth factor‑2 from bacte‑
rial inclusion bodies used as cell culture substrates. Acta Biomater. 
2014;10(3):1354–9.
 33. Torrealba D, Parra D, Seras‑Franzoso J, Vallejos‑Vidal E, Yero D, Gibert I, et al. 
Nanostructured recombinant cytokines: a highly stable alternative to short‑
lived prophylactics. Biomaterials. 2016;107:102–14.
 34. García‑Fruitós E, González‑Montalbán N, Morell M, Vera A, Ferraz RM, Arís A, 
et al. Aggregation as bacterial inclusion bodies does not imply inactivation 
of enzymes and fluorescent proteins. Microb Cell Fact. 2005;4:1–6.
 35. García‑Fruitós E editor. Insoluble proteins methods and protocols. New York: 
Springer; 2015. (Methods in molecular biology; vol. 1258). http://link.sprin 
ger.com/10.1007/978‑1‑4939‑2205‑5.
 36. Shi L, Wu Y, Yang C, Ma Y, Zhang Q, Huang W, et al. Effect of nicotine on 
Staphylococcus aureus biofilm formation and virulence factors. Sci Rep. 
2019;9(1):20243.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub‑
lished maps and institutional affiliations.
